Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    Subscribe
    • Home
    • Top Stories
    • Business
    • Tech
    • Companies
    • Events
    • Announcements
    Home»Asia Business»Novotech Partners with South Korea’s Pusan National University Hospital
    Asia Business

    Novotech Partners with South Korea’s Pusan National University Hospital

    Marie JonesBy Marie JonesJune 18, 2020Updated:June 20, 2020No Comments3 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Low_Novotech200618The leading Asia-Pacific biotech specialist CRO Novotech has partnered with South Korea’s world-class Pusan National University Hospital (PNUH) based in Busan, South Korea’s second largest city.

    The Partnership is designed to further support Novotech’s biotech clients run their clinical trials in the region.

    Dr. Jeong Zoo Lee, the President of PNUH, said: “The PNUH site team and Novotech have worked together on a number of studies already. Based on our strong relationship, we have progressed to a formal agreement to support Novotech biotech clients across all clinical research and patient recruitment areas.

    “We are pleased to partneri with a regional CRO leader with such an outstanding reputation internationally,” said Dr. Lee.

    Dr. Yooni Kim, Executive Director, Asia Operations said: “Novotech was very pleased to establish a Partnership with PNUH which has completed more than 340 clinical trials and is ranked 7th in terms of number of clinical trials in South Korea (GlobalData).

    “The PNUH site offers biotechs quality infrastructure, world-class medical and hospital facilities, as well as South Korea’s supportive rapid start-up environment. South Korea is the most active country in clinical research in Asia after China.

    “The main therapeutic areas for clinical trials at PNUH have been oncology, infectious disease, cardiovascular and gastrointestinal,” said Dr. Kim.

    Novotech now has over 20 significant Partnerships with some of the leading medical institutions in the region. The Partnership Program is strategically designed to deliver unparalleled access to quality investigators, KOLs, and up to 4 million patients for its international biotech clients.

    About Novotech – https://novotech-cro.com

    Novotech is internationally recognized as the leading regional full-service contract research organization (CRO) in Asia-Pacific. Novotech has been instrumental in the success of over a thousand Phase I – IV clinical trials for biotechnology companies. Novotech was established in 1996, with offices in 11 locations across the region, and site partnerships with major health institutions.

    Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech obtained the ISO 27001 certification which is the best-known standard in the ISO family providing requirements for an Information Security Management System. Together with the ISO 9001 Quality Management system, Novotech aims at the highest IT security and quality standards for patients and biotechnology companies.

    For RFP enquiries: Please fill out the form available at https://novotech-cro.com/talk-to-an-expert

    Media contact:

    David James

    communications@novotech-cro.com

    AU: +61 2 8218 2144

    USA: +1 415 951 3228

    Asia: +65 3159 3427

    Novotech
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleThere is still a role for the office in a post Covid-19 world, says TEC
    Next Article eSense-Lab Inks Deal with Wise Winery for Terpenes-Infused Sanitisers

    Related Posts

    ASN 2026: HighTide Therapeutics Presents New HTD1801 Data Highlighting Therapeutic Potential in Chronic Kidney Disease

    October 23, 2026

    New Global Initiative Seeks to Modernize Health Workforce Mobility

    October 22, 2026

    Hong Kong International Optical Fair opens in November

    October 21, 2026
    Add A Comment

    Comments are closed.

    Latest News

    • GA-ASI Partnering With Spirit Defense For FQ-42 CCA Production
    • Study Finds Lower Rates of Overweight Among Vegan-Fed Cats
    • Savills Hong Kong Hosts Grand Reception to Celebrate 40th Anniversary, Over 300 Guests Gather to Mark Glorious Milestone
    • ASN 2026: HighTide Therapeutics Presents New HTD1801 Data Highlighting Therapeutic Potential in Chronic Kidney Disease
    • MicroVision Begins Commercial Production of MOVIA(TM) Pro for Superior Short-Range Sensing and Onboard Perception, Enabling Physical AI at the Edge
    • New Global Initiative Seeks to Modernize Health Workforce Mobility
    • P&G, Nestle, Mars, AstraZeneca, ITC and Bekaert win OMP Supply Chain Awards
    • Zhipu, Jiangmen, QuantGroup and Other Investors Join Forces to Back RMB 1 Billion Cognitive Intelligence Venture Capital Fund for Physical AI Ecosystem Development
    • Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA Date of March 25, 2027
    • Chervon Appoints Stephen Sarnocinski to President – End User Research, Sales and Service – OPE Commercial Landscaping Market Global
    © 2026 BusinessNewsAsia.com
    • About Us
    • Contact Us
    • BusinessNews.ph
    • AsiaPEVC.com
    • DevFiNews.com
    • RenewableEnergy.ph

    Type above and press Enter to search. Press Esc to cancel.